Status:

TERMINATED

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Lead Sponsor:

Patricia I. Dickson, M.D.

Collaborating Sponsors:

The Ryan Foundation

University of California, Los Angeles

Conditions:

Mucopolysaccharidosis I

Lysosomal Storage Diseases

Eligibility:

All Genders

8+ years

Phase:

PHASE1

Brief Summary

The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MP...

Detailed Description

Enzyme replacement therapy (ERT) has been developed for mucopolysaccharidosis I (MPS I), a lysosomal storage disorder. ERT helps many physical ailments due to the disease, but does not treat the centr...

Eligibility Criteria

Inclusion

  • Hurler-Scheie,Scheie form of MPS I, of Hurler 2 years after hematopoietic stem cell transplantation
  • Spinal cord compression
  • Age greater than 8 years
  • Able to provide legal informed consent
  • Aware of clinical treatment option of observation without treatment or surgical decompression
  • Negative urine pregnancy test at screening (non-sterile females of child-bearing potential only)
  • Currently using two acceptable methods of birth control (non-sterile females of child-bearing potential who are sexually active only)
  • Willing and able to comply with study procedures

Exclusion

  • Severe (Hurler) form of MPS I
  • Desires surgical or medical treatment of spinal cord compression
  • Spinal cord compression that warrants immediate surgical intervention
  • Pregnancy or lactation
  • Hematopoietic stem cell transplantation within 2 years of study enrollment
  • Receipt of an investigational drug within 30 days of enrollment
  • Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration
  • Significant anti-iduronidase antibody titer
  • Recent initiation of intravenous laronidase (within past 6 months)
  • Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2011

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT00215527

Start Date

November 1 2005

End Date

October 1 2011

Last Update

February 21 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Los Angeles Biomedical Research Institute at Harbor-UCLA ( LA BioMed )

Torrance, California, United States, 90502

2

Helsinki University Central Hospital

Helsinki, Finland, FI-00014

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I | DecenTrialz